Mindray(SZ:300760) Huan Qiu Lao Hu Cai Jing·2025-10-15 06:50Core Viewpoint - Mindray Medical has officially initiated the process for its H-share listing on the Hong Kong Stock Exchange, aiming to enhance its capital strength and support its internationalization strategy [1] Group 1: Listing and Capital Strategy - The company plans to issue up to 10% of its total share capital, with an additional 15% over-allotment option for underwriters [1] - The move is part of Mindray's commitment to its "internationalization" strategy, aiming to build an international capital platform to meet business development needs [1] Group 2: Overseas Market Expansion - Mindray has been actively expanding into overseas markets, having previously listed on the New York Stock Exchange in 2006 and later privatized in 2016 due to low P/E ratios [2] - The company has made significant acquisitions since 2008, including Datascope and Zonare, and has established local production in 14 countries with 12 R&D centers globally [2] - In 2024, overseas sales are projected to account for 45% of total revenue, reaching 16.4 billion, with a target to increase this to 70% [2] Group 3: Financial Performance - The company's total revenue for the first half of the year was 16.743 billion, a decline of 18.45%, with net profit dropping by 32.96% [3] - Domestic revenue fell by approximately 33% to 8.41 billion due to delays in medical equipment tenders, while overseas revenue grew by 5.39% to 8.332 billion [2][3] - Despite the revenue decline, Mindray maintains strong financial health, with total assets of 58.77 billion and net assets of 44.02 billion as of June [3]